Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.

Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW.

J Med Chem. 2004 Jan 15;47(2):355-74.

PMID:
14711308
2.

Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.

Julius RL, Hawthorne MF.

Drug News Perspect. 2008 Jun;21(5):258-66. doi: 10.1358/dnp.2008.21.5.1219011. Review.

PMID:
18596990
3.

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW.

Acc Chem Res. 2005 Dec;38(12):911-21. Review.

PMID:
16359163
4.

TTR fibril formation inhibitors: is there a SAR?

Nencetti S, Orlandini E.

Curr Med Chem. 2012;19(15):2356-79. Review.

PMID:
22471984
5.

Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.

Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):587-96. Review.

PMID:
16266291
6.

Transthyretin amyloidosis: a tale of weak interactions.

Saraiva MJ.

FEBS Lett. 2001 Jun 8;498(2-3):201-3. Review.

7.

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.

Sekijima Y, Kelly JW, Ikeda S.

Curr Pharm Des. 2008;14(30):3219-30. Review.

PMID:
19075702
8.

[Transthyretin: it's miracle function and pathogenesis].

Ando Y.

Rinsho Byori. 2009 Mar;57(3):228-35. Review. Japanese.

PMID:
19363993
9.

[Immunological and serological laboratory tests: transthyretin].

Ando Y.

Rinsho Byori. 2005 Jun;53(6):554-7. Review. Japanese.

PMID:
16026084
10.

Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.

Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA.

Curr Opin Struct Biol. 2010 Feb;20(1):54-62. doi: 10.1016/j.sbi.2009.12.009. Epub 2010 Feb 3. Review.

11.

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW.

J Mol Biol. 2012 Aug 10;421(2-3):185-203. doi: 10.1016/j.jmb.2011.12.060. Epub 2012 Jan 5. Review.

12.

Computational studies on transthyretin.

Ortore G, Martinelli A.

Curr Med Chem. 2012;19(15):2380-7. Review.

PMID:
22471985
13.

From the globular to the fibrous state: protein structure and structural conversion in amyloid formation.

Sunde M, Blake CC.

Q Rev Biophys. 1998 Feb;31(1):1-39. Review. No abstract available.

PMID:
9717197
14.

[Current role of transthyretin in clinical biology].

FĂ©rard G, Ingenbleek Y.

Ann Biol Clin (Paris). 2003 May-Jun;61(3):358-62. Review. French. No abstract available.

Supplemental Content

Support Center